Skip to main content
AMCP Nexus 2023 Main banner

Drugs, Diseases, and the Managed Care Impact

(D3) Managed Care Oncology Perspectives: CAR T-cells vs BiTEs

Tuesday, October 17, 2023
3:15 PM – 4:30 PM East Coast USA Time
Location: Sabal
CPE
ACPE UAN:0233-0000-23-051-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
Understanding the landscape of cell therapy continues to be a challenge for many health plans. As more chimeric antigen receptor (CAR) T-cell and bispecific T-cell engager (BiTE) therapies are approved in the same cancers and stages, along with the concern that most agents lack Phase 3 clinical trial data or long-term follow-up, determining the value of these treatments has been a great challenge. Faculty will provide a discussion outlining CAR T and BiTE agents currently approved, their place in therapy, the challenges providers, patients, and payers face, and review the current drug development pipeline. In addition, we will present potential solutions and managed care strategies for administering these highly expensive drug classes.

Learning Objectives::

At the completion of this activity, participants should be able to:
  1. Review the evolution, mechanism of action, clinical efficacy, and place in therapy for both CAR T-cells and BiTEs currently available in the market.
  2. Discuss the new and emerging products in the CAR T and BiTE pipeline.
  3. Describe the impact on patients, providers, and payers, including financial implications.
  4. Identify potential managed care strategies that provide solutions for oversight and management.